UPClytics
View all cases

UPC CFI 2821/2026

Aug 5, 2026·EP2401365: REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION

Case details
Status
Written Phase
Action
Other
Category
Other Procedural
Parties
Respondents
Representatives
  • Georg Rauh
Division
Munich LD
Technology
Biotechnology
Language
English
Documents
Document titleDatePublic
action.publishOrderDecision.case2026-09-09Not public
Receipt2026-09-03Not public
Cover sheet2026-09-03Not public
Document2026-09-03Not public
action.communication.general2026-09-02Not public
Receipt2026-09-01Not public
Cover sheet2026-09-01Not public
Document2026-09-01Not public
Receipt2026-08-05Not public
Cover sheet2026-08-05Not public
Application document Applicant2026-08-05Not public
Other cases on the same patent
Other cases involving the same parties
  • 2026-07-16UPC CFI 2562/2026Genevant Sciences GmbH v Pfizer, Inc.
  • 2026-07-16UPC CFI 2566/2026Genevant Sciences GmbH v Pfizer, Inc.
  • 2025-08-20UPC CFI 768/2025Enanta Pharmaceuticals, Inc. v Pfizer, Inc.
  • 2025-07-03UPC CFI 620/2025GlaxoSmithKline Biologicals SA v C.P. Pharmaceuticals International C.V.
  • 2025-07-03UPC CFI 621/2025GlaxoSmithKline Biologicals SA v C.P. Pharmaceuticals International C.V.
  • 2024-11-15UPC CFI 687/2024Pfizer S.r.l. v GlaxoSmithKline Biologicals SA
  • 2024-08-14UPC CFI 476/2024Pfizer, Inc. v GlaxoSmithKline Biologicals SA
  • 2024-08-05UPC CFI 468/2024GlaxoSmithKline Biologicals SA v Pfizer Europe MA EEIG
  • UPC APP 16306/2025GlaxoSmithKline Biologicals SA v Pfizer Europe MA EEIG
  • UPC APP 16366/2025Pfizer, Inc. v GlaxoSmithKline Biologicals SA

More cases: Munich LD·2026